Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus MYHIBBIN.
MICONAZOLE 7 vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Primarily fecal (~50%) and renal (~<1% unchanged)
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category A/B
Category C
Antifungal
Antifungal